Use of sGC stimulators for the treatment of mitochondrial disorders
The present disclosure relates to methods, uses, pharmaceutical compositions comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of a mitochondrial disorder.
1. A method of treating MELAS (Mitochondrial myopathy, encephalomyopathy, lactic acidosis, stroke-like symptoms) in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of an sGC stimulator or a pharmaceutically acceptable salt thereof, wherein the sGC stimulator or a pharmaceutically acceptable salt thereof, is represented by the following formula:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein said sGC stimulator, or a pharmaceutically acceptable salt thereof, is administered in combination with arginine or citrulline.
3. A method of treating MELAS (Mitochondrial myopathy, encephalomyopathy, lactic acidosis, stroke-like symptoms) in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of an sGC stimulator, wherein the sGC stimulator is represented by the following formula:
4. The method of claim 3 , wherein said sGC stimulator is administered in combination with arginine or citrulline.